ArticleHemaSphere2024

Outcomes and prognostic factors in 3306 patients with relapsed/refractory chronic lymphocytic leukemia treated with ibrutinib outside of clinical trials: A nationwide study.

Gian Matteo Rigolin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.